Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Table 3 Therapeutic regimens

Regimens	Dose	Days of administration
R-HyperCVAD regimen
Cycle A
Rituximab	375 mg/m²	1
Cyclophosphamide	300 mg/m² every 12 h	2–4
Vincristine	1.4 mg/m²	4, 11
Doxorubicin	50 mg/m²	4
Dexamethasone	40 mg per day	1–4, 11–14
Cycle B
Rituximab	375 mg/m²	1
Methotrexate	1 g/m² continuous intravenous infusion for 24 h	2
Cytarabine	3 g/m² every 12 h	3, 4
DA-EPOCH-R regimen ^a
Rituximab	375 mg/m²	1
Etoposide	50 mg/m² continuous intravenous infusion for 24 h	2–5
Doxorubicin	10 mg/m² continuous intravenous infusion for 24 h	2–5
Vincristine	0.4 mg/m² continuous intravenous infusion for 24 h	2–5
Cyclophosphamide	750 mg/m²	6
Prednisone	60 mg/m²	2–6
DA-EPOCH-R/MA regimen
DA-EPOCH-R
Rituximab	375 mg/m²	1
Etoposide	50 mg/m² continuous intravenous infusion for 24 h	2–5
Doxorubicin	10 mg/m² continuous intravenous infusion for 24 h	2–5
Vincristine	0.4 mg/m² continuous intravenous infusion for 24 h	2–5
Cyclophosphamide	750 mg/m²	6
Prednisone	60 mg/m²	2–6
Alternating with MA
Methotrexate	3 g/m²	1
Cytarabine	2 g/m² every 12 h	2–3
Intrathecal prophylaxis
Methotrexate	10 mg
Dexamethasone	10 mg
Cytarabine	50 mg

PB-DHL primary breast double-hit lymphoma, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA, rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine, MA high-dose methotrexate and cytarabine, IV intravenous infusion
^aThe doses of etoposide, doxorubicin, and cyclophosphamide were adjusted according to criteria [23, 35]

ISSN: 1475-2867